Wolverine combines two recovery peptides, BPC-157 and TB-500, in one protocol. This page covers what each peptide is, how it is thought to work, what the evidence does and does not support, and our view on whether it is worth using.
It also covers why, with any injected peptide, the source matters as much as the molecule. The protocol itself is individualized and set with a physician.
Reviewed by Dr. David Oliak, board-certified surgeon
Updated August 2026
Wolverine is a blend of BPC-157 and TB-500, prescribed together to support the body's repair and recovery processes. It is one of the most requested peptide protocols we offer.
BPC-157 — short for "body protection compound" — is a synthetic peptide based on a protective protein first identified in human gastric juice, and studied in animal models since the 1990s. In animal and laboratory studies it has been associated with tissue repair — new blood-vessel formation; recovery in muscle, tendon, ligament, and bone; reduced inflammation; and support of the gut lining. It is the more structural-repair component of the pair.
TB-500 is a synthetic version of the active region of Thymosin Beta-4, a repair peptide the body produces naturally that was first characterized decades ago. In preclinical research it has been associated with the migration of repair cells to injured tissue, support of healing, and reduced inflammation and scarring. It is oriented more toward mobility and whole-body recovery.
Prescribed together, they are intended to support repair across complementary mechanisms. This picture is drawn from preclinical research; it has not been established in human clinical trials.
Patients most often consider Wolverine for recovery from injury and for support of tendons, ligaments, muscle, and joints. They also consider it for management of inflammation and gut health.
The aim is to support the body's own repair processes — to recover faster and more completely from an injury, a hard training block, or the accumulated wear that slows healing over time. These are the reported and studied applications of the two peptides, not established, FDA-approved indications.
Where the evidence stands for each peptide.
The supporting evidence is primarily animal research and substantial anecdotal reports of faster healing and recovery. In our own practice, we have found BPC-157 and TB-500 effective for accelerating recovery and healing in many, if not most, patients, and it is one of our more popular and well-received protocols. Rigorous human trials remain limited.
Our verdict: the preclinical basis is strong, the anecdotal experience is large and favorable, and in our own practice most patients report improved recovery and healing. But the organized human-trial data is limited, so this is promising, not proven.
On balance we are comfortable prescribing Wolverine for recovery and repair goals, as a supervised therapy: the safety signal is reasonable, and the research and what we see in our patients point the same way.
What we are not willing to do is present it as established, or let a patient rely on an unverified online product for an injected peptide.
And we use it the way we use any peptide: as one targeted tool, chosen for a defined recovery goal and matched to the patient, within a plan we have thought through. It is not a vial used in isolation. Whether it fits you is a clinical judgment we make together.
— Dr. David Oliak, board-certified physician and surgeon
Wolverine is given by subcutaneous injection in cycles, and the protocol is individualized — the figures below are general frameworks, not a prescription, and your dose is set with your physician.
Combined, it is commonly dosed daily, five days a week, in the range of about 0.25 to 0.5 mg per day, with some protocols higher, cycled with a break.
It can also be dosed as the two peptides separately, which some patients prefer. BPC-157 is taken daily; TB-500, which has a longer duration of action, is usually given only once or twice a week at a higher per-dose amount.
Whether to combine the two or dose them separately is largely a practical choice, convenience versus flexibility, rather than one settled by strong comparative evidence. There are no rigorous human trials pitting the approaches against each other.
In our experience the combined blend is convenient and effective; separate dosing suits patients who want TB-500 on its less-frequent schedule.
(general only; your protocol is set at the consult)
These are general frameworks, not a prescription. The peptides, the dose, the schedule, and whether to combine or separate them are individualized in consultation.
With any injected peptide, the source is a safety issue, not a detail. We prescribe Wolverine compounded for human use by a licensed pharmacy, on a prescription, and supervise its use.
Most peptides sold online are labeled "research use only" — not for human use — and are produced without a regulatory framework to confirm their contents, purity, or sterility. For an injected product that matters a great deal.
Reported side effects of the peptides themselves are generally mild, most often local irritation at the injection site; human data is limited, which is another reason we prescribe and monitor rather than leave it unsupervised.
Wolverine is not an FDA-approved medication. Why "research use only" peptides are a problem →
Let's begin
Whether Wolverine fits your goals is decided in a consultation. If so, which peptides, at what dose, and whether to combine or separate them are decided there too.
The protocol is set within a plan built around what you are trying to achieve. That plan uses Wolverine on its own for a focused recovery goal, or as one part of a broader plan when your goals call for it.
Book a peptide consult for a targeted goal, or start with a comprehensive evaluation when you want the fuller picture first. To speak with us first, call 714-671-2005.
Why "research use only" peptides are a problem
KLOW: BPC-157, TB-500, and KPV
GHK-Cu and GLOW for skin, hair, and repair
What a comprehensive evaluation includes